Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP9 | P14780 | 13/20 | 0.76 |
| ▸ | MMP8 | P22894 | 12/20 | 0.76 |
| ▸ | MMP2 | P08253 | 11/20 | 0.76 |
| ▸ | MMP1 | P03956 | 7/20 | 0.76 |
| ▸ | FCER2 | P06734 | 4/20 | 0.76 |
| ▸ | MMP7 | P09237 | 3/20 | 0.76 |
| ▸ | MMP3 | P08254 | 2/20 | 0.76 |
| ▸ | MMP12 | P39900 | 2/20 | 0.76 |
| ▸ | MMP13 | P45452 | 2/20 | 0.76 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5502507 | 0.86 | MMP2 (1.00) | MMP9MMP8MMP2MMP1FCER2 | |
| SCHEMBL7383258 | 0.85 | MMP1 (0.87) | MMP9MMP8MMP2MMP1FCER2 | |
| SCHEMBL7370927 | 0.83 | MMP1 (0.93) | MMP9MMP8MMP2MMP1FCER2 | |
| SCHEMBL7370922 | 0.83 | MMP1 (0.93) | MMP9MMP8MMP2MMP1FCER2 | |
| SCHEMBL7370918 | 0.83 | MMP1 (0.93) | MMP9MMP8MMP2MMP1FCER2 | |
| SCHEMBL4421988 | 0.82 | MMP2 (0.79) | MMP9MMP8MMP2MMP1FCER2 | |
| SCHEMBL6271207 | 0.78 | MMP9 (0.72) | MMP9MMP8MMP2MMP1FCER2 | |
| SCHEMBL29928916 | 0.78 | MMP9 (0.93) | MMP9MMP8MMP2MMP1FCER2 | |
| SCHEMBL12513228 | 0.77 | MMP1 (0.71) | MMP9MMP8MMP2MMP1FCER2 | |
| SCHEMBL314933 | 0.76 | MMP9 (0.81) | MMP9MMP8MMP2MMP1FCER2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070293937-A1 | Endoluminal medical device for local delivery of cathepsin inhibitors, method of making and treating | MED INSTITUTE, INC. | 2007-12-20 | — | — | US | disclosed |
| US-20070293937-A1 | Endoluminal medical device for local delivery of cathepsin inhibitors, method of making and treating | MED INSTITUTE, INC. | 2007-12-20 | — | — | US | disclosed |
| WO-2007081530-A2 | ENDOLUMINAL MEDICAL DEVICE FOR LOCAL DELIVERY OF CATHEPSIN INHIBITORS | MED INSTITUTE, INC. (US) | 2007-07-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070293937-A1 | Endoluminal medical device for local delivery of cathepsin inhibitors, method of making and treating | CTSS, CTSD, CTSV | MMP9 91/4885MMP8 95/4885MMP2 47/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.